News

01/19/2024

GENERIUM – the first in Russia to receive a registration certificate for a biomedical cell product

The first advanced therapy medicinal product (ATMP) in Russia was registered by GENERIUM under the trade name EASYTENSE. It is an autologous product based on chondrocytes, the main cells of cartilage tissue, and is intended for the restoration of damage to the cartilage of the knee joint with a defect area of up to 10 square cm.

12/07/2023

GENERIUM has registered a biosimilar of ranibizumab, a medicine for treatment of age-related macular degeneration

The medicine from GENERIUM under the trade name Laxolan® received a registration certificate from the Ministry of Health. It is intended to treat age-related macular degeneration, as well as certain other retinal diseases that are a common cause of vision loss.

10/16/2023

The first biosimilar of romiplostim has been registered in Russia

02/09/2022

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

01/28/2022

Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World

The 13th meeting of the Russian-Arab Business Council session was held on 25-26 January.

02/23/2021

Russia shows off new Covid-19 vaccine factory even as its people hesitate to get the shot

Volginsky, Russia (CNN) — Decades ago, Soviet scientists researched biological weapons at a site in Volginsky, about 70 miles east of Moscow. Now, that site is being used to mass-produce a vaccine aimed at protecting people around the world from the coronavirus.

01/21/2021

Talks on production of Russian vaccine in Serbia commence

Minister without portfolio in charge of innovations and technological development Nenad Popovic visited today the production capacities of the largest Russian vaccine manufacturer "Sputnik V" - Generium in the Vladimir region in Russia.

10/27/2020

GENERIUM launched the production of Sputnik V vaccine

Moscow, 26 October 2020. The Ministry of Health of the Russian Federation has included a biotechnology company GENERIUM in the marketing authorisation as a manufacturer of Gam-COVID-Vac (Sputnik V) vaccine for the prevention of COVID-19.

10/20/2020

First Russian omalizumab biosimilar registered for the treatment of severe bronchial asthma

Moscow, 19 October 2020. GENERIUM, a Russian biotechnology company, received a marketing authorisation (MA) for the first national biosimilar of a recombinant (genetically engineered) humanised monoclonal antibody (mAb) to immunoglobulin E (IgE)—omalizumab (Genolair®) for the treatment of persistent atopic bronchial asthma of mean and severe degree.

06/05/2020

GENERIUM became the first company registered a unique combination of high-precision tests for the detection of antibodies of three classes to the SARS-CoV-2 coronavirus (COVID-19)

Moscow, Russia, 5 June 2020. GENERIUM, a leading Russian biopharmaceutical company involved in the development and production of pharmaceutical products for the diagnosis and treatment of orphan, oncological and socially significant diseases has registered three unique test systems for the detection of specific anti-SARS-CoV-2 antibodies of the IgA, IgM and IgG classes by the enzyme-linked immunosorbent assay (ELISA).